Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

Brain scientists are offering a new reason to control blood sugar levels: It might help lower your risk of developing Alzheimer's disease.

"There's many reasons to get [blood sugar] under control," says David Holtzman, chairman of neurology at Washington University in St. Louis. "But this is certainly one."

Educators refer to teens like Alex as "twice exceptional."

"I have a large degree of skill in almost every subject of learning," says Alex, who is 16. "But I also have autistic spectrum disorder."

For Alex, this dual identity has meant both opportunity and frustration.

He has skipped two grades so far, and began taking college math courses last year, when he was still 15. But when he was younger, Alex's underdeveloped social skills caused him a lot of grief.

"I was constantly getting into fights and normally losing them," he says.

The link between vaping and severe lung problems is getting a lot of attention.

But scientists say they're also worried about vaping's effect on teenage brains.

"Unfortunately, the brain problems and challenges may be things that we see later on down the road," says Nii Addy, associate professor of psychiatry and cellular and molecular physiology at Yale School of Medicine.

Too much physical exertion appears to make the brain tired.

That's the conclusion of a study of triathletes published Thursday in the journal Current Biology.

Researchers found that after several weeks of overtraining, athletes became more likely to choose immediate gratification over long-term rewards. At the same time, brain scans showed the athletes had decreased activity in an area of the brain involved in decision-making.

Researchers are beginning to understand why certain brain cancers are so hard to stop.

Three studies published Wednesday in the journal Nature found that these deadly tumors integrate themselves into the brain's electrical network and then hijack signals from healthy nerve cells to fuel their own growth.

The depression drug esketamine, marketed as Spravato, appears to offer quick relief to people who are actively considering suicide.

Esketamine, a chemical cousin of the anesthetic and party drug ketamine, reduced depression symptoms within hours in two large studies of suicidal patients, the drug's maker announced Monday.

By the time a fetus is 6 months old, it is producing electrical signals recognizable as brain waves.

And clusters of lab-grown human brain cells known as organoids seem to follow a similar schedule, researchers reported Thursday in the journal Cell Stem Cell.

In mice, scientists have used a variety of drugs to treat brain disorders including murine versions of Alzheimer's disease, depression and schizophrenia. But in people, these same treatments usually fail.

And now researchers are beginning to understand why.

A detailed comparison of the cell types in mouse and human brain tissue found subtle but important differences that could affect the response to many drugs, a team reports Wednesday in the journal Nature.

A close look at the brains of 40 U.S. Embassy workers in Cuba who developed mysterious symptoms has found no evidence of injury. The State Department has said the employees were hurt by some sort of attack.

Researchers are prescribing exercise as if it were a drug in a study that aims to see if it can prevent Alzheimer's disease.

"We are testing if exercise is medicine for people with a mild memory problem," says Laura Baker, principal investigator of the nationwide EXERT study and associate director of the Alzheimer's Disease Research Center at Wake Forest School of Medicine.

Pages